We consider no immunization versus massimmunization reaching 30% of the population.
2
Its rivals such as Sanofi-Aventis, Novartis and AstraZeneca are also poised to benefit from governments' massimmunization campaigns.
3
In response to the pandemic H1N1 influenza 2009 outbreak, many jurisdictions undertook massimmunization programs that were among the largest in recent history.